# Comparison of Artificial Neural Network with Logistic Regression as Classification Models for Variable Selection for Prediction of Breast Cancer Patient Outcomes

Authors: Valérie Bourdès; Stéphane Bonnevay; Paolo Lisboa; Rémy Defrance; David Pérol; Sylvie Chabaud; Thomas Bachelot; Thérèse Gargi; Sylvie Négrier
Journal: Advances in Artificial Neural Systems
 (2010)

---

## Abstract

The aim of this study was to compare multilayer perceptron neural networks (NNs) with standard logistic regression (LR) to identify key covariates impacting on mortality from cancer causes, disease-free survival (DFS), and disease recurrence using Area Under Receiver-Operating Characteristics (AUROC) in breast cancer patients. From 1996 to 2004, 2,535 patients diagnosed with primary breast cancer entered into the study at a single French centre, where they received standard treatment. For specific mortality as well as DFS analysis, the ROC curves were greater with the NN models compared to LR model with better sensitivity and specificity. Four predictive factors were retained by both approaches for mortality: clinical size stage, Scarff Bloom Richardson grade, number of invaded nodes, and progesterone receptor. The results enhanced the relevance of the use of NN models in predictive analysis in oncology, which appeared to be more accurate in prediction in this French breast cancer cohort.


---

## Body

## 1. Introduction

Artificial Neural Networks (ANNs) have been extensively used in many research areas from marketing to medicine [1]. They first received much attention from computer scientists, neurophysiologists, psychologists, and engineers, interested in biological nervous system organization and artificial intelligence. Their two main applications in medicine are pattern recognition (classification) and prediction: during these last years (from 1990s and increasing in the 2000s), the applications for prognostic and diagnostic classification in medicine have attracted growing interest in the medical literature. They have been applied to make predictions in numerous fields such as cardiology, molecular biology, trauma outcomes, neonatology, and oncology (acute myeloma, prostatic cancer, colon cancer, and breast cancer) [2–7]. A review of evidence of ANN benefit in the medical field has been published [1].ANNs are particularly useful in prediction where highly nonlinear approaches are required to sift through the plethora of available information. They present the main advantage of not being based on “a priori” assumptions and of allowing detection of links between factors that conventional statistical techniques such as logistic regression may not be able to detect. With the increasing number of potential prognostic factors for breast cancer, it is becoming increasingly more difficult to integrate the combination of these factors into an accurate prediction of individual clinical course. The main pragmatic impact of allocating patients into prognostic risks is the disease management with the choice of treatment.The logistic regression in this work was chosen as an accepted standard for prediction by biostatisticians [8] in order to evaluate the neural network.


## 2. Materials and Methods

### 2.1. Data Base Recruitment and Followup

Since 1996, all patients whose initial surgical treatment (lumpectomy or mastectomy) was performed at the Centre Léon Bérard (CLB) (primary or secondary following neoadjuvant chemotherapy), based in Lyon, have been registered in the database. Tumour diagnosis was confirmed by histology and concerned infiltrating orin situ carcinoma; the data were collected by a clinical research assistant (CRA) at the CLB from the patient’s computer medical record file. Followup was provided until patient’s death (letter to the referring physician, or registrar’s office) as well as information on the evolution of the tumour in terms of local or distal recurrences. An in-house algorithm has been developed to detect the administrative area where the patients live. This breast cancer database was updated regularly according to the consecutive clinical cases treated at the CLB. About 220 explanatory variables have been captured, including the clinical or surgical history of the patient, the histology of the tumour, the treatments applied, and some immuno-histochemical covariates (hormonal status, Her2+). By the end of March 2006, a total of 4,070 events were stored in the database, corresponding to 3,929 patients.


### 2.2. Cohort Selection

In order to work on a more homogeneous type of malignant disease, records concerningin situ carcinomas without infiltrating component were not taken into account in this analysis. As some patients had more than one record (141), only the first episode defined by the earlier date of diagnosis was selected. For 40 patients, two records were available for the first diagnosis, corresponding to bilateral tumours. These cases were not included into the analysis as we could not decide which histology was more influential on survival parameters. With the same objective, namely, to compare only “pure” cases, patients with a history of ipsilateral or contralateral carcinoma not treated at the CLB were not taken into account. As the aim of this project was to work out new prognosis tools, it was decided to leave out patients with initial metastatic carcinoma who were considered as specific and with a poor prognosis. Finally, all the patients with a date of diagnosis prior to December 31st, 2004 were included. After this cohort selection, 2,535 records corresponding to 2,535 different patients were selected for this work. A total of 32 parameters including clinical, histological, immunohistochemical, and treatment variables were considered as relevant by the clinicians and were used for the analysis (Table 1).Table 1
Variables included in the database.
Variables
Modalities
Breast side
Right, Left
Age
Real
Delay diagnosis—1st treatment
Time
Personal cancer history
No, Yes
Menopausal status
No, Yes
Cutaneous inflammation
No, Yes
Skin invasion
No, Yes
Clinical number of nodules
0, 1, ≥2
Clinical T stage (size)
T0, T1, T2, T3, T4
Clinical N stage
N0, N+
Number of tumours (histology)
0 or 1,≥2
Tumour size (mm) (histology)
Real
Histological type
Lobular, Ductal, Mixed, Microinvasive, Others
SBR grade
1, 2, 3
Lymphatic embolus
No, Yes
Nervous colonisation
No, Yes
Necrosis (histology)
Noin situ component,
In situ component without necrosis
In situ component with necrosis
Infiltrating tumour associated with CIS
Others,>75% in situ
Limits of exeresis—infiltrating carcinoma
Notin sano, In sano
Skin—infiltrating tumour
No or Not Applicable, Yes
Skin—embolus
No or Not Applicable, Yes
Nipple—infiltrating tumour
No or Not Applicable, Yes
Nipple—cancer in situ
No or Not Applicable, Yes
Nipple—embolus
No or Not Applicable, Yes
Nipple—Paget’s disease
No or Not Applicable, Yes
Pectoral muscle invaded
No or Not Applicable, Yes
Number of invaded nodes
0, 1 or 2,≥3
Nodes invaded
N0, Micro metastasis, Macrometastasis
Capsular breaking
No, Yes
Oestrogen receptor: % marked cells (count)
<10%, (10–50)%, >50%
Oestrogen receptor (intensity)
+, ++/+++
Progesterone receptor: % marked cells (count)
<10%,[10–50]%, >50%
Progesterone receptor (intensity)
+, ++/+++


### 2.3. Events of Interest to Be Analysed

The following four events of interest were defined and analysed: mortality attributed to cancer causes (specific mortality) (136 patients, 5.4%), disease-free survival (DFS) (372 patients, 14.8%), local recurrence (113 patients, 4.5%), and metastatic distal recurrence (242 patients, 9.6%).For all analyses, a patient was considered to have a recurrence if the patient’s status in the followup form was not ticked as “complete response”, if an “evolution form” for this patient was filled up, or if there was a second record in the initial breast database for this patient. Local recurrence was confirmed if an “evolution form” with the local part was fulfilled or if there was a second record in the initial breast database for this patient, with a clinical stage assessed as M0. Distal recurrence was confirmed if an “evolution form” with the distal part was fulfilled or if there was a second record in the initial breast database for this patient, with clinical stage assessed as M+.


### 2.4. Variables Selection of Neural Networks

To compare logistic regression (LR) and neural networks (NNs) models, many papers use the same variables for both input models (the variables selected by the multivariate analysis) [9]. This choice is justified by the large degree of overlap between the sets of variables selected with both approaches. But in this paper, we decided to build two NN models for each analysis according to their inputs: the first one with the multivariate selected variables (used for the LR models, i.e., NN-varLR) and the second one with the variables selected with our NN approach, i.e., NN-varNN). To select the most significant variables for use with neural networks, we used three different methods: forward and backward stepwise feature selection and a genetic input selection algorithm. Forward selection consists in choosing the most predictable variable then checks for a second variable that, added to the first, most improves the model; this process is repeated until either all variables have been selected or no further improvement is made. Backward stepwise feature selection is the reverse process: it starts with all the variables and then removes a variable at each stage which less degrades the model. Genetic algorithm selection is a heuristic seeking the optimal set of input variables. This heuristic builds a model by a succession of artificial transformations (mutation, crossover, and selection) from an initial population of variables sets. Each of our genetic selections was made from a population of 100 individuals (one individual corresponds to one set of variables) on 100 generations. Each set of variables corresponds to a binary string where a 0 indicates that the variable is not in the set of variables, and a 1 indicates that the variable is in this set. This set is tested with the help of a neural network, and the objective function is the error of this neural network on a training set.Each of these methods has some advantages and disadvantages. Forward selection is faster than the others, but it may miss key variables if they are interdependent. Backward selection does not suffer from this problem, but it is time consuming at the beginning of the process due to the evaluations of the whole set of variables. Genetic algorithm selection is the slowest method.With our choice (100 individuals and 100 generations), it performs 10,000 evaluations of sets of variables. For example, the selection of one set of variables is about 60 times longer with the genetic algorithm than the backward selection, but genetic algorithms are well suited for feature selection as there is a large number of possible variables. Because of their differences and complementarities, we decided to combine these three methods to select the inputs of our NN models.With a view to improving the generalization capability of networks and to decreasing the network size and execution size, a penalty can be used to penalise the large sets of variables [10]. In this way, a penalty parameter is multiplied by the number of selected variables and added to the error level. Following different analyses, we finally used a small penalty equal to 0.0001 with half of selection algorithms and no penalty with the other half selection algorithms. Each method calculates the value of the set of covariates selected at each step while building the neural network. As, during the learning and test phases, data are chosen and presented at random, then, training and validation sets are different, and then results are different too. According to some experiments, we have chosen to perform each method 40 times: 20 without penalty and 20 with a penalty equal to 0.0001. Indeed, 120 (3 × 40) selections were performed. In order to illustrate our variables selections, Table 2 shows the selection results for the prediction of “mortality from cancer causes”.Table 2
Details of variables selections for “specific mortality”.
Forward
Forward
Backward
Backward
Genetic
Genetic
Global
0.0001
0.0
0.0001
0.0
0.0001
0.0
#
%
#
%
#
%
#
%
#
%
#
%
#
%
Side of Breast
0
0%
4
20%
0
0%
4
20%
0
0%
4
20%
12
10%
History of Cancer
0
0%
11
55%
0
0%
10
50%
1
5%
4
20%
26
22%
Menopausal
16
80%
19
95%
19
95%
17
85%
17
85%
19
95%
107
89%
Cutaneous inflam
0
0%
4
20%
0
0%
3
15%
0
0%
3
15%
10
8%
Skin invasion
6
30%
14
70%
3
15%
11
55%
5
25%
13
65%
52
43%
Clin. Nb. Nodules
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%
Invaded Nodes
20
100%
19
95%
20
100%
19
95%
20
100%
20
100%
118
98%
Stade N
16
80%
19
95%
18
90%
18
90%
14
70%
20
100%
105
88%
Nb of tum (histo)
8
40%
16
80%
6
30%
20
100%
5
25%
18
90%
73
61%
Size of tum (histo)
0
0%
4
20%
0
0%
5
25%
0
0%
3
15%
12
10%
SBR Grade
19
95%
20
100%
19
95%
20
100%
20
100%
20
100%
118
98%
Lymphatic Embolus
14
70%
15
75%
13
65%
18
90%
13
65%
14
70%
87
73%
Nervous spread
0
0%
11
55%
4
20%
7
35%
1
5%
6
30%
29
24%
Limits Exeresis
0
0%
10
50%
0
0%
8
40%
0
0%
5
25%
23
19%
Skin infiltating
2
10%
9
45%
7
35%
8
40%
0
0%
11
55%
37
31%
Skin embolus
0
0%
6
30%
0
0%
2
10%
0
0%
2
10%
10
8%
Nipple infiltrating
1
5%
4
20%
0
0%
4
20%
0
0%
3
15%
12
10%
Nipple Cancer in situ
0
0%
4
20%
0
0%
1
5%
0
0%
1
5%
6
5%
Nipple embolus
2
10%
5
25%
0
0%
3
15%
1
5%
3
15%
14
12%
Nipple Paget
0
0%
9
45%
0
0%
10
50%
0
0%
5
25%
24
20%
Pectoral muscle inv
0
0%
5
25%
0
0%
3
15%
0
0%
3
15%
11
9%
Age
6
30%
18
90%
5
25%
19
95%
7
35%
19
95%
74
62%
Time diag-firstTreat
0
0%
2
10%
0
0%
2
10%
0
0%
0
0%
4
3%
Time diag-firstSurgery
0
0%
8
40%
0
0%
11
55%
0
0%
6
30%
25
21%
Histology
19
95%
19
95%
20
100%
20
100%
20
100%
20
100%
118
98%
Necrosis
11
55%
16
80%
13
65%
16
80%
15
75%
13
65%
84
70%
Infiltrating tumour
0
0%
8
40%
0
0%
11
55%
1
5%
11
55%
31
26%
Clinical Size
20
100%
20
100%
19
95%
20
100%
20
100%
19
95%
118
98%
Capsular breaking
18
90%
19
95%
12
60%
19
95%
17
85%
18
90%
103
86%
Oestro receptors
19
95%
18
90%
17
85%
20
100%
17
85%
16
80%
107
89%
Progest receptors
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%
Nb. Nodes Invad
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%For each method, Table2 indicates how many times these variables have been selected and the corresponding percentage. The last column “Global” gives the total number of selections. For example, “Nervous Spread” has never been selected by the forward selection method with a 0.0001 penalty. It has been selected 11 times by the same method without penalty. The last row shows that the “Progesterone Receptors” variable has always been selected by all methods. The last column of this table takes into account results selection combination of all the methods. The problem is to determine a threshold α that decides whether a variable will be included or not in our model. To fix this threshold, we built and evaluated some NN models with different combinations of variables according to their global percentage. According to these experimental results, we decided that a variable would be kept as an input for our model if it was selected in at least 95% of our 120 selections. Moreover, this value of 95% leads to the inclusion of a reasonable number of variables regarding the complexity of the NN models. This final selection obtained was validated and approved by the oncologists of Centre Leon Berard.


### 2.5. Building Neural Networks

ANNs have been applied in a wide range of problems and have given, in many cases, superior results to standard statistical models [11]. In particular, the predictive reliability of ANN models has been demonstrated in medical diagnosis [12]. According to the literature and some previous experimental analyses, we decided to use the Multilayer Perceptrons (MLP) for predictions [13]. In this work, we used only one type of ANNs for different reasons. First our study was dealing with 4 different analyses, and, for each one, two NN models were built for both variables selections; secondly, MLP is the most commonly used ANN. For each analysis and each set of input variables, we built a three-layer network with an input layer corresponding to our risk factors (selected variables), a hidden layer with hyperbolic activation functions, and one linear output unit modelling the dichotomous risk outcome (Figure 1).Figure 1
Architecture of a feed-forward supervised 3-Layer Perceptron neural network.The number of neurons on the hidden layer was determined according to the number and the nature of variables at the entry. Weights and bias of neural network are determined by training with a two-phase procedure. The first phase is a quite short burst of backpropagation, with a moderate training rate. The second phase is a longer run of conjugated gradient descent, a much more powerful algorithm, which is less likely to encounter convergence problems than otherwise due to the use of backpropagation first. During this learning process, the weights in a MLP are adjusted using least squares fitting together with the training two-phase procedure to minimize a root mean square error function. In order to interpret the network outputs as probabilities and to make them comparable to the results of logistic regression, we used a cross entropy error function to adjust weights. This cross entropy function is specially designed for classification problems where it is used in combination with hyperbolic activation function [14].A continuous input value is prescaled to a range between 0 and 1; a two-state nominal variable, which corresponds to one entry of the neural network, is represented by transformation into a numeric value (e.g., “Skin invasion” = 0 or 1); a many-state nominal variable is recoded into as many binary entries as modalities (on Figure1, x1 is a 5-state nominal variable which correspond to 5 inputs, and xn is a 3-state nominal variable which correspond to 3 inputs).The objective is to generate neural networks not too close to the data used for the learning phase (to avoid overfitting) in order to build a consistent predictor that can be used with other data (those not used for the learning phase). To obtain networks with a strong capacity of generalisation, we divided data randomly in two datasets:(i)
a learning set to build the models (LR  and NN),(ii)
a testing set for the evaluation (this set is not used for construction).The learning set was composed of 1,775 individuals (about 70% of total population), with 153 deaths (72.2% of death) and 267 disease-free survivals (71.2% of disease-free survival). The testing set was composed of 760 individuals, 59 deaths, and 105 disease-free survivals. For this paper, one LR model and two NN models were built for each event to analyse. The first neural network model was built according to the logistic regression inputs (selected variables from logistic regression analysis), and the second one with the neural network selected variables approaches.


### 2.6. Statistics

With a view to selecting the prognostic factors of the LR model, an univariate logistic analysis was first performed for each event. Then, all the variables significant at the level of 10% were included in the multivariate logistic step. Neural network constructions, as well as the selection of significant covariates for these models, were performed with the Statistical Neural Networks software release 7.1. The logistic regression was performed with SAS Sofware 9.1. A total of 36 variables were extracted from the database: 32 covariates (Table1) and 4 events of interest. To prevent introducing bias we decided that not all the surgical and treatment variables were taken into account for both LR and NN analysis. A total of 2,535 observations were analysed. Only 0.6% missing data were recorded in the CLB database. Due to their paucity, they were not coded as a separate attribute, and only the available data were used for modelling.The comparison between the three models, LR, NN with inputs of LR selection (NN-varLR), and NN with inputs of NN selection (NN-varNN), was assessed using AUROC (Area Under Receiver-Operating Characteristics). The area under curve is a good measure of the overall predictive accuracy of an analytic tool. It represents a plot of sensitivityversus 1 minus specificity. Sensitivity measures the fraction of positive cases classified as positive, and specificity measures the fraction of negative cases classified as negative. ROC indicator in this work measures the separation between the probability distributions of the output neuron activation under the null hypothesis (no event at the end of October 2004) and under the alternative hypothesis (event at the end of December 2004).


## 2.1. Data Base Recruitment and Followup

Since 1996, all patients whose initial surgical treatment (lumpectomy or mastectomy) was performed at the Centre Léon Bérard (CLB) (primary or secondary following neoadjuvant chemotherapy), based in Lyon, have been registered in the database. Tumour diagnosis was confirmed by histology and concerned infiltrating orin situ carcinoma; the data were collected by a clinical research assistant (CRA) at the CLB from the patient’s computer medical record file. Followup was provided until patient’s death (letter to the referring physician, or registrar’s office) as well as information on the evolution of the tumour in terms of local or distal recurrences. An in-house algorithm has been developed to detect the administrative area where the patients live. This breast cancer database was updated regularly according to the consecutive clinical cases treated at the CLB. About 220 explanatory variables have been captured, including the clinical or surgical history of the patient, the histology of the tumour, the treatments applied, and some immuno-histochemical covariates (hormonal status, Her2+). By the end of March 2006, a total of 4,070 events were stored in the database, corresponding to 3,929 patients.


## 2.2. Cohort Selection

In order to work on a more homogeneous type of malignant disease, records concerningin situ carcinomas without infiltrating component were not taken into account in this analysis. As some patients had more than one record (141), only the first episode defined by the earlier date of diagnosis was selected. For 40 patients, two records were available for the first diagnosis, corresponding to bilateral tumours. These cases were not included into the analysis as we could not decide which histology was more influential on survival parameters. With the same objective, namely, to compare only “pure” cases, patients with a history of ipsilateral or contralateral carcinoma not treated at the CLB were not taken into account. As the aim of this project was to work out new prognosis tools, it was decided to leave out patients with initial metastatic carcinoma who were considered as specific and with a poor prognosis. Finally, all the patients with a date of diagnosis prior to December 31st, 2004 were included. After this cohort selection, 2,535 records corresponding to 2,535 different patients were selected for this work. A total of 32 parameters including clinical, histological, immunohistochemical, and treatment variables were considered as relevant by the clinicians and were used for the analysis (Table 1).Table 1
Variables included in the database.
Variables
Modalities
Breast side
Right, Left
Age
Real
Delay diagnosis—1st treatment
Time
Personal cancer history
No, Yes
Menopausal status
No, Yes
Cutaneous inflammation
No, Yes
Skin invasion
No, Yes
Clinical number of nodules
0, 1, ≥2
Clinical T stage (size)
T0, T1, T2, T3, T4
Clinical N stage
N0, N+
Number of tumours (histology)
0 or 1,≥2
Tumour size (mm) (histology)
Real
Histological type
Lobular, Ductal, Mixed, Microinvasive, Others
SBR grade
1, 2, 3
Lymphatic embolus
No, Yes
Nervous colonisation
No, Yes
Necrosis (histology)
Noin situ component,
In situ component without necrosis
In situ component with necrosis
Infiltrating tumour associated with CIS
Others,>75% in situ
Limits of exeresis—infiltrating carcinoma
Notin sano, In sano
Skin—infiltrating tumour
No or Not Applicable, Yes
Skin—embolus
No or Not Applicable, Yes
Nipple—infiltrating tumour
No or Not Applicable, Yes
Nipple—cancer in situ
No or Not Applicable, Yes
Nipple—embolus
No or Not Applicable, Yes
Nipple—Paget’s disease
No or Not Applicable, Yes
Pectoral muscle invaded
No or Not Applicable, Yes
Number of invaded nodes
0, 1 or 2,≥3
Nodes invaded
N0, Micro metastasis, Macrometastasis
Capsular breaking
No, Yes
Oestrogen receptor: % marked cells (count)
<10%, (10–50)%, >50%
Oestrogen receptor (intensity)
+, ++/+++
Progesterone receptor: % marked cells (count)
<10%,[10–50]%, >50%
Progesterone receptor (intensity)
+, ++/+++


## 2.3. Events of Interest to Be Analysed

The following four events of interest were defined and analysed: mortality attributed to cancer causes (specific mortality) (136 patients, 5.4%), disease-free survival (DFS) (372 patients, 14.8%), local recurrence (113 patients, 4.5%), and metastatic distal recurrence (242 patients, 9.6%).For all analyses, a patient was considered to have a recurrence if the patient’s status in the followup form was not ticked as “complete response”, if an “evolution form” for this patient was filled up, or if there was a second record in the initial breast database for this patient. Local recurrence was confirmed if an “evolution form” with the local part was fulfilled or if there was a second record in the initial breast database for this patient, with a clinical stage assessed as M0. Distal recurrence was confirmed if an “evolution form” with the distal part was fulfilled or if there was a second record in the initial breast database for this patient, with clinical stage assessed as M+.


## 2.4. Variables Selection of Neural Networks

To compare logistic regression (LR) and neural networks (NNs) models, many papers use the same variables for both input models (the variables selected by the multivariate analysis) [9]. This choice is justified by the large degree of overlap between the sets of variables selected with both approaches. But in this paper, we decided to build two NN models for each analysis according to their inputs: the first one with the multivariate selected variables (used for the LR models, i.e., NN-varLR) and the second one with the variables selected with our NN approach, i.e., NN-varNN). To select the most significant variables for use with neural networks, we used three different methods: forward and backward stepwise feature selection and a genetic input selection algorithm. Forward selection consists in choosing the most predictable variable then checks for a second variable that, added to the first, most improves the model; this process is repeated until either all variables have been selected or no further improvement is made. Backward stepwise feature selection is the reverse process: it starts with all the variables and then removes a variable at each stage which less degrades the model. Genetic algorithm selection is a heuristic seeking the optimal set of input variables. This heuristic builds a model by a succession of artificial transformations (mutation, crossover, and selection) from an initial population of variables sets. Each of our genetic selections was made from a population of 100 individuals (one individual corresponds to one set of variables) on 100 generations. Each set of variables corresponds to a binary string where a 0 indicates that the variable is not in the set of variables, and a 1 indicates that the variable is in this set. This set is tested with the help of a neural network, and the objective function is the error of this neural network on a training set.Each of these methods has some advantages and disadvantages. Forward selection is faster than the others, but it may miss key variables if they are interdependent. Backward selection does not suffer from this problem, but it is time consuming at the beginning of the process due to the evaluations of the whole set of variables. Genetic algorithm selection is the slowest method.With our choice (100 individuals and 100 generations), it performs 10,000 evaluations of sets of variables. For example, the selection of one set of variables is about 60 times longer with the genetic algorithm than the backward selection, but genetic algorithms are well suited for feature selection as there is a large number of possible variables. Because of their differences and complementarities, we decided to combine these three methods to select the inputs of our NN models.With a view to improving the generalization capability of networks and to decreasing the network size and execution size, a penalty can be used to penalise the large sets of variables [10]. In this way, a penalty parameter is multiplied by the number of selected variables and added to the error level. Following different analyses, we finally used a small penalty equal to 0.0001 with half of selection algorithms and no penalty with the other half selection algorithms. Each method calculates the value of the set of covariates selected at each step while building the neural network. As, during the learning and test phases, data are chosen and presented at random, then, training and validation sets are different, and then results are different too. According to some experiments, we have chosen to perform each method 40 times: 20 without penalty and 20 with a penalty equal to 0.0001. Indeed, 120 (3 × 40) selections were performed. In order to illustrate our variables selections, Table 2 shows the selection results for the prediction of “mortality from cancer causes”.Table 2
Details of variables selections for “specific mortality”.
Forward
Forward
Backward
Backward
Genetic
Genetic
Global
0.0001
0.0
0.0001
0.0
0.0001
0.0
#
%
#
%
#
%
#
%
#
%
#
%
#
%
Side of Breast
0
0%
4
20%
0
0%
4
20%
0
0%
4
20%
12
10%
History of Cancer
0
0%
11
55%
0
0%
10
50%
1
5%
4
20%
26
22%
Menopausal
16
80%
19
95%
19
95%
17
85%
17
85%
19
95%
107
89%
Cutaneous inflam
0
0%
4
20%
0
0%
3
15%
0
0%
3
15%
10
8%
Skin invasion
6
30%
14
70%
3
15%
11
55%
5
25%
13
65%
52
43%
Clin. Nb. Nodules
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%
Invaded Nodes
20
100%
19
95%
20
100%
19
95%
20
100%
20
100%
118
98%
Stade N
16
80%
19
95%
18
90%
18
90%
14
70%
20
100%
105
88%
Nb of tum (histo)
8
40%
16
80%
6
30%
20
100%
5
25%
18
90%
73
61%
Size of tum (histo)
0
0%
4
20%
0
0%
5
25%
0
0%
3
15%
12
10%
SBR Grade
19
95%
20
100%
19
95%
20
100%
20
100%
20
100%
118
98%
Lymphatic Embolus
14
70%
15
75%
13
65%
18
90%
13
65%
14
70%
87
73%
Nervous spread
0
0%
11
55%
4
20%
7
35%
1
5%
6
30%
29
24%
Limits Exeresis
0
0%
10
50%
0
0%
8
40%
0
0%
5
25%
23
19%
Skin infiltating
2
10%
9
45%
7
35%
8
40%
0
0%
11
55%
37
31%
Skin embolus
0
0%
6
30%
0
0%
2
10%
0
0%
2
10%
10
8%
Nipple infiltrating
1
5%
4
20%
0
0%
4
20%
0
0%
3
15%
12
10%
Nipple Cancer in situ
0
0%
4
20%
0
0%
1
5%
0
0%
1
5%
6
5%
Nipple embolus
2
10%
5
25%
0
0%
3
15%
1
5%
3
15%
14
12%
Nipple Paget
0
0%
9
45%
0
0%
10
50%
0
0%
5
25%
24
20%
Pectoral muscle inv
0
0%
5
25%
0
0%
3
15%
0
0%
3
15%
11
9%
Age
6
30%
18
90%
5
25%
19
95%
7
35%
19
95%
74
62%
Time diag-firstTreat
0
0%
2
10%
0
0%
2
10%
0
0%
0
0%
4
3%
Time diag-firstSurgery
0
0%
8
40%
0
0%
11
55%
0
0%
6
30%
25
21%
Histology
19
95%
19
95%
20
100%
20
100%
20
100%
20
100%
118
98%
Necrosis
11
55%
16
80%
13
65%
16
80%
15
75%
13
65%
84
70%
Infiltrating tumour
0
0%
8
40%
0
0%
11
55%
1
5%
11
55%
31
26%
Clinical Size
20
100%
20
100%
19
95%
20
100%
20
100%
19
95%
118
98%
Capsular breaking
18
90%
19
95%
12
60%
19
95%
17
85%
18
90%
103
86%
Oestro receptors
19
95%
18
90%
17
85%
20
100%
17
85%
16
80%
107
89%
Progest receptors
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%
Nb. Nodes Invad
20
100%
20
100%
20
100%
20
100%
20
100%
20
100%
120
100%For each method, Table2 indicates how many times these variables have been selected and the corresponding percentage. The last column “Global” gives the total number of selections. For example, “Nervous Spread” has never been selected by the forward selection method with a 0.0001 penalty. It has been selected 11 times by the same method without penalty. The last row shows that the “Progesterone Receptors” variable has always been selected by all methods. The last column of this table takes into account results selection combination of all the methods. The problem is to determine a threshold α that decides whether a variable will be included or not in our model. To fix this threshold, we built and evaluated some NN models with different combinations of variables according to their global percentage. According to these experimental results, we decided that a variable would be kept as an input for our model if it was selected in at least 95% of our 120 selections. Moreover, this value of 95% leads to the inclusion of a reasonable number of variables regarding the complexity of the NN models. This final selection obtained was validated and approved by the oncologists of Centre Leon Berard.


## 2.5. Building Neural Networks

ANNs have been applied in a wide range of problems and have given, in many cases, superior results to standard statistical models [11]. In particular, the predictive reliability of ANN models has been demonstrated in medical diagnosis [12]. According to the literature and some previous experimental analyses, we decided to use the Multilayer Perceptrons (MLP) for predictions [13]. In this work, we used only one type of ANNs for different reasons. First our study was dealing with 4 different analyses, and, for each one, two NN models were built for both variables selections; secondly, MLP is the most commonly used ANN. For each analysis and each set of input variables, we built a three-layer network with an input layer corresponding to our risk factors (selected variables), a hidden layer with hyperbolic activation functions, and one linear output unit modelling the dichotomous risk outcome (Figure 1).Figure 1
Architecture of a feed-forward supervised 3-Layer Perceptron neural network.The number of neurons on the hidden layer was determined according to the number and the nature of variables at the entry. Weights and bias of neural network are determined by training with a two-phase procedure. The first phase is a quite short burst of backpropagation, with a moderate training rate. The second phase is a longer run of conjugated gradient descent, a much more powerful algorithm, which is less likely to encounter convergence problems than otherwise due to the use of backpropagation first. During this learning process, the weights in a MLP are adjusted using least squares fitting together with the training two-phase procedure to minimize a root mean square error function. In order to interpret the network outputs as probabilities and to make them comparable to the results of logistic regression, we used a cross entropy error function to adjust weights. This cross entropy function is specially designed for classification problems where it is used in combination with hyperbolic activation function [14].A continuous input value is prescaled to a range between 0 and 1; a two-state nominal variable, which corresponds to one entry of the neural network, is represented by transformation into a numeric value (e.g., “Skin invasion” = 0 or 1); a many-state nominal variable is recoded into as many binary entries as modalities (on Figure1, x1 is a 5-state nominal variable which correspond to 5 inputs, and xn is a 3-state nominal variable which correspond to 3 inputs).The objective is to generate neural networks not too close to the data used for the learning phase (to avoid overfitting) in order to build a consistent predictor that can be used with other data (those not used for the learning phase). To obtain networks with a strong capacity of generalisation, we divided data randomly in two datasets:(i)
a learning set to build the models (LR  and NN),(ii)
a testing set for the evaluation (this set is not used for construction).The learning set was composed of 1,775 individuals (about 70% of total population), with 153 deaths (72.2% of death) and 267 disease-free survivals (71.2% of disease-free survival). The testing set was composed of 760 individuals, 59 deaths, and 105 disease-free survivals. For this paper, one LR model and two NN models were built for each event to analyse. The first neural network model was built according to the logistic regression inputs (selected variables from logistic regression analysis), and the second one with the neural network selected variables approaches.


## 2.6. Statistics

With a view to selecting the prognostic factors of the LR model, an univariate logistic analysis was first performed for each event. Then, all the variables significant at the level of 10% were included in the multivariate logistic step. Neural network constructions, as well as the selection of significant covariates for these models, were performed with the Statistical Neural Networks software release 7.1. The logistic regression was performed with SAS Sofware 9.1. A total of 36 variables were extracted from the database: 32 covariates (Table1) and 4 events of interest. To prevent introducing bias we decided that not all the surgical and treatment variables were taken into account for both LR and NN analysis. A total of 2,535 observations were analysed. Only 0.6% missing data were recorded in the CLB database. Due to their paucity, they were not coded as a separate attribute, and only the available data were used for modelling.The comparison between the three models, LR, NN with inputs of LR selection (NN-varLR), and NN with inputs of NN selection (NN-varNN), was assessed using AUROC (Area Under Receiver-Operating Characteristics). The area under curve is a good measure of the overall predictive accuracy of an analytic tool. It represents a plot of sensitivityversus 1 minus specificity. Sensitivity measures the fraction of positive cases classified as positive, and specificity measures the fraction of negative cases classified as negative. ROC indicator in this work measures the separation between the probability distributions of the output neuron activation under the null hypothesis (no event at the end of October 2004) and under the alternative hypothesis (event at the end of December 2004).


## 3. Results

### 3.1. Cohort Analysis

The main characteristics of the cohort are described in Table3. Median age was 54 years ranging from 23 to 92 years. A total of 69 patients (2.7%) had a history of previous cancer; 69% of patients were in menopausal status. Clinical T stage was >2 in 10% of the cases, and clinical N stage was positive in 17% of patients. In 12% of the cases the diagnosis was multi focal. The histological median tumour size was 20 mm with a range from 0.4 to 250 mm. The carcinoma was found ductal in more than 70% of the cases with a SBR (Scarff Bloom Richardson) grade 1, 2, and 3 in 24%, 47%, and 30%, respectively. The percentage of marked cells was ≥ to 50% for progesterone receptors (PRs) in 54% of the cases and for oestrogen receptors (ERs) in 76%.Table 3
Main characteristics of the cohort.
Clinical parameters
Age
Mean± SD
N
=
2535
59.8± 12.1
Median [range]
54.0 [23.2; 91.7]
Breast side
Left
N
=
2535
50.1%
Right
49.9%
Personal cancer history*
N
=
2535
2.7%
Menopausal status
N
=
2506
68.7%
Skin invasion
N
=
2531
4.4%
Cutaneous inflammation
N
=
2529
1.9%
Clinical number of nodules
0
22.9%
1
N
=
2525
74.3%
≥2
2.7%
Clinical T stage (size)
T0
22.2%
T1
44.9%
T2
N
=
2573
22.0%
T3
4.9%
T4
5.9%
Clinical N stage
N+
N
=
2525
17.3%
Histological parameters
Number of tumours (histology)
0 or 1
N
=
2459
88.2%
≥2
11.8%
Tumour size (mm) (histology)
Mean± SD
N
=
2452
24.1 ± 20.1
Median (range)
20.0 [0.4; 250.0]
Histological type
Lobular
10.0%
Ductal
73.6%
Mixed
N
=
2535
3.7%
Micro invasive
1.5%
Others
11.2%
Histological grade (SBR)
1
23.5%
2
N
=
2449
47.2%
3
29.3%
Lymphatic embolus
N
=
2523
36.8%
Nervous colonisation
N
=
2520
13.7%
Necrosis (histology)
Noin situ component
19.5%
In situ component without  necrosis
N
=
2534
35.0%
In situ component with  necrosis
45.4%
Infiltrating tumour associated with CIS
>75% in situ
N
=
2535
5.5%
Limits of exeresis—infiltrating carcinoma
Notin sano
N
=
2496
2.5%
Skin—infiltrating tumour
N
=
2535
5.6%
Skin—embolus
N
=
2535
2.0%
Nipple—infiltrating tumour
N
=
2535
7.7%
Nipple—cancerin situ
N
=
2535
6.8%
Nipple—embolus
N
=
2535
4.0%
Nipple—Paget’s disease
N
=
2535
1.3%
Pectoral muscle invaded
N
=
2535
1.4%
Number of invaded nodes:
0
52.0%
1 or 2
N
=
2515
28.2%
≥3
19.8%
Invaded nodes:
N0
8.5%
Micrometastasis
N
=
2535
58.9%
Macrometastasis
32.7%
Capsular breaking
N
=
2535
26.0%
Immunohistochemical parameters
Oestrogen receptor: % marked cells (count):
<10%
17.1%
10–50%
N
=
2443
7.2%
≥50%
75.8%
Oestrogen receptor (intensity):
+
N
=
2030
25.8%
++ and +++
74.2%
Progesterone receptor: % marked cells (count)
<10%
28.2%
10%–50%
N
=
2443
17.4%
≥50%
54.4%
Progesterone receptor (intensity):
+
N
=
1796
17.4%
++ and +++
82.6%
6
*9 patients had cancer history. Localizations were 16 gynaecologic, 11 digestive, 11 Hodgkin/LMNH, 8 melanoma, 7 thyroid, 4 lung, 4 head and neck, 4 urinary, and 3 others.Overall mortality occurred in 8.4% of cases and specific mortality in 5.4% of cases. A total of 316 progressions were notified (12.5%) representing at least 4.5% of local recurrences and 8.4% of metastatic events. The median followup was 4.1 years (CI95% = 4.0–4.5) with a maximum followup of 10.2 years.


### 3.2. Events

Table4(b) displays the results of the selections from statistical and neural networks approaches for “Specific Mortality”. A variable was chosen by the neural approach if the percentage of selection was greater or equal to 95% (bold data of column NN), and a variable was chosen by the logistic regression analysis when a cross is matched in the corresponding column LR. Four variables among the five selected by the logistic regression were retained by both approaches, either LR or the NN approach, namely, “Progesterone receptor”, “Number nodes invaded”, “Clinical size stage”, and “SBR grade”. In addition to these common variables, the NN approach selected, with high percentages, the variables “Histology”, “Invaded nodes”, and “Clinical number of nodules”. On the other hand, the multivariate analysis selected the “Skin embolus” whereas this variable was only selected in 8% of cases by the NN selection.Table 4
Variables selections for Logistic Regression and Neural Network approaches.
(a)
Disease-free survival.
Variables
NN
LR
Invaded nodes
100%
X
Clinical size stage
100%
X
Number nodes invaded
100%
X
SBR grade
98%
X
Histology
98%
Necrosis
98%
Oestrogen receptors
74%
X
Skin infiltrating tumour
21%
X
(b)
Mortality from cancer causes.
Variables
NN
LR
Clinical number nodules
100%
Progesterone receptor
100%
X
Number nodes invaded
100%
X
Clinical size stage
98%
X
SBR grade
98%
X
Histology
98%
Invaded nodes
98%
Skin embolus
8%
X
(c)
Local recurrence.
Variables
NN
LR
Number nodes invaded
98%
X
Lymphatic embolus
95%
X
Ganglion invaded
95%
Necrosis
95%
X
Oestrogen receptors
95%
X
Histology
48%
X
Number tumours
15%
X
Skin invasion
13%
X
(d)
Metastatic recurrence.
Variables
NN
LR
Clinical Size stage
100%
X
Invaded nodes
100%
Progesterone receptors
100%
X
Number of nodes invaded
100%
X
SBR grade
98%
X
Histology
98%
Oestrogen receptors
85%
XTables4(a), 4(c), and 4(d) display variables selections from LR and NN approaches of “Disease free survival”, “Local recurrences”, and “Distal recurrences” analyses.The architecture of MLP neural models for “Specific Mortality” analysis according to variable selection is the following.(i)
NN-varLR. The best model of NN obtained with the inputs of the LR selection (Table4(b)) is described as follows.
(a)
One input layer corresponds to the 5 covariates. The skin embolus covariate, with 2 modalities, corresponds to a binary entry. The other covariates are recoded into as many entries as modalities (3 covariates with 3 modalities and 1 covariate with 5 modalities). The network built that way has 15 binary entries.(b)
One hidden layer composed of 6 neurons with hyperbolic activation function.(c)
One output layer composed of one neurone with logistic activation function.The same types of MLP were built for “Disease free survival”, “Local recurrences”, and “Distal recurrences” analysis.(ii)
NN-varNN. The best model of NN obtained with the inputs of the NN selection (Table4(b)) is described as follows.
(a)
One input layer corresponding to the 7 covariates. These covariates are recoded into as many entries as modalities (5 covariates with 3 modalities, 1 covariate with 4 modalities, and 1 covariate with 5 modalities). The network built that way has 24 binary entries.(b)
One hidden layer composed of 6 hidden units with hyperbolic activation functions.(c)
One output layer composed of one neurone with logistic activation functions.The same types of MLP were built for “Disease free survival”, “Local recurrences”, and “Distal recurrences” analyses.ROC Curves
According to “Specific Mortality”, the AUROC curves of “Specific Mortality” were very similar between the three models with a slight superiority in favour of the NN models (Figure2(b)). The corresponding sensitivity and specificity optimal values are given in Table 5(b).
Figures2(a), 2(c), and 2(d) display AUROC curves, and sensitivity and Tables 5(a), 5(c), and 5(d) display specificity optimal values for the event “Disease-Free survival”, “Local recurrences”, and “Distal recurrences” analyses.Table 5
Sensitivity and specificity.
(a)
Disease-free survival.
LR
NN-varLR
NN-varNN
Sensitivity
71.5
82.2
80.3
Specificity
68.9
77.9
79.3
False negative rate
28.5
17.8
19.7
False positive rate
31.1
22.1
20.7
Positive predictive value
11.9
18.0
18.6
(b)
Mortality from cancer causes.
LR
NN-varLR
NN-varNN
Sensitivity
80.5
86.7
87.5
Specificity
77.9
76.0
77.3
False negative rate
19.5
13.3
12.5
False positive rate
22.1
24.0
22.7
Positive predictive value
17.4
17.2
18.2
(c)
Local recurrence.
LR
NN-varLR
NN-varNN
Sensitivity
68.6
72.4
72.9
Specificity
65.1
66.7
64.9
False negative rate
31.4
27.6
27.1
False positive rate
34.9
33.3
35.1
Positive predictive value
8.3
9.1
8.8
(d)
Metastatic recurrence.
LR
NN-varLR
NN-varNN
Sensitivity
71.3
70.6
71.9
Specificity
78.1
78.8
78.5
False negative rate
28.7
29.4
28.1
False positive rate
21.9
21.2
21.5
Positive predictive value
25.9
26.4
26.4ROC curves from LR, NN-varLR, and NN-varNN models. (a) Disease-free survival. (b) Mortality from cancer causes. (c) Local recurrence. (d) Metastatic recurrence.
(a)
(b)
(c)
(d)


## 3.1. Cohort Analysis

The main characteristics of the cohort are described in Table3. Median age was 54 years ranging from 23 to 92 years. A total of 69 patients (2.7%) had a history of previous cancer; 69% of patients were in menopausal status. Clinical T stage was >2 in 10% of the cases, and clinical N stage was positive in 17% of patients. In 12% of the cases the diagnosis was multi focal. The histological median tumour size was 20 mm with a range from 0.4 to 250 mm. The carcinoma was found ductal in more than 70% of the cases with a SBR (Scarff Bloom Richardson) grade 1, 2, and 3 in 24%, 47%, and 30%, respectively. The percentage of marked cells was ≥ to 50% for progesterone receptors (PRs) in 54% of the cases and for oestrogen receptors (ERs) in 76%.Table 3
Main characteristics of the cohort.
Clinical parameters
Age
Mean± SD
N
=
2535
59.8± 12.1
Median [range]
54.0 [23.2; 91.7]
Breast side
Left
N
=
2535
50.1%
Right
49.9%
Personal cancer history*
N
=
2535
2.7%
Menopausal status
N
=
2506
68.7%
Skin invasion
N
=
2531
4.4%
Cutaneous inflammation
N
=
2529
1.9%
Clinical number of nodules
0
22.9%
1
N
=
2525
74.3%
≥2
2.7%
Clinical T stage (size)
T0
22.2%
T1
44.9%
T2
N
=
2573
22.0%
T3
4.9%
T4
5.9%
Clinical N stage
N+
N
=
2525
17.3%
Histological parameters
Number of tumours (histology)
0 or 1
N
=
2459
88.2%
≥2
11.8%
Tumour size (mm) (histology)
Mean± SD
N
=
2452
24.1 ± 20.1
Median (range)
20.0 [0.4; 250.0]
Histological type
Lobular
10.0%
Ductal
73.6%
Mixed
N
=
2535
3.7%
Micro invasive
1.5%
Others
11.2%
Histological grade (SBR)
1
23.5%
2
N
=
2449
47.2%
3
29.3%
Lymphatic embolus
N
=
2523
36.8%
Nervous colonisation
N
=
2520
13.7%
Necrosis (histology)
Noin situ component
19.5%
In situ component without  necrosis
N
=
2534
35.0%
In situ component with  necrosis
45.4%
Infiltrating tumour associated with CIS
>75% in situ
N
=
2535
5.5%
Limits of exeresis—infiltrating carcinoma
Notin sano
N
=
2496
2.5%
Skin—infiltrating tumour
N
=
2535
5.6%
Skin—embolus
N
=
2535
2.0%
Nipple—infiltrating tumour
N
=
2535
7.7%
Nipple—cancerin situ
N
=
2535
6.8%
Nipple—embolus
N
=
2535
4.0%
Nipple—Paget’s disease
N
=
2535
1.3%
Pectoral muscle invaded
N
=
2535
1.4%
Number of invaded nodes:
0
52.0%
1 or 2
N
=
2515
28.2%
≥3
19.8%
Invaded nodes:
N0
8.5%
Micrometastasis
N
=
2535
58.9%
Macrometastasis
32.7%
Capsular breaking
N
=
2535
26.0%
Immunohistochemical parameters
Oestrogen receptor: % marked cells (count):
<10%
17.1%
10–50%
N
=
2443
7.2%
≥50%
75.8%
Oestrogen receptor (intensity):
+
N
=
2030
25.8%
++ and +++
74.2%
Progesterone receptor: % marked cells (count)
<10%
28.2%
10%–50%
N
=
2443
17.4%
≥50%
54.4%
Progesterone receptor (intensity):
+
N
=
1796
17.4%
++ and +++
82.6%
6
*9 patients had cancer history. Localizations were 16 gynaecologic, 11 digestive, 11 Hodgkin/LMNH, 8 melanoma, 7 thyroid, 4 lung, 4 head and neck, 4 urinary, and 3 others.Overall mortality occurred in 8.4% of cases and specific mortality in 5.4% of cases. A total of 316 progressions were notified (12.5%) representing at least 4.5% of local recurrences and 8.4% of metastatic events. The median followup was 4.1 years (CI95% = 4.0–4.5) with a maximum followup of 10.2 years.


## 3.2. Events

Table4(b) displays the results of the selections from statistical and neural networks approaches for “Specific Mortality”. A variable was chosen by the neural approach if the percentage of selection was greater or equal to 95% (bold data of column NN), and a variable was chosen by the logistic regression analysis when a cross is matched in the corresponding column LR. Four variables among the five selected by the logistic regression were retained by both approaches, either LR or the NN approach, namely, “Progesterone receptor”, “Number nodes invaded”, “Clinical size stage”, and “SBR grade”. In addition to these common variables, the NN approach selected, with high percentages, the variables “Histology”, “Invaded nodes”, and “Clinical number of nodules”. On the other hand, the multivariate analysis selected the “Skin embolus” whereas this variable was only selected in 8% of cases by the NN selection.Table 4
Variables selections for Logistic Regression and Neural Network approaches.
(a)
Disease-free survival.
Variables
NN
LR
Invaded nodes
100%
X
Clinical size stage
100%
X
Number nodes invaded
100%
X
SBR grade
98%
X
Histology
98%
Necrosis
98%
Oestrogen receptors
74%
X
Skin infiltrating tumour
21%
X
(b)
Mortality from cancer causes.
Variables
NN
LR
Clinical number nodules
100%
Progesterone receptor
100%
X
Number nodes invaded
100%
X
Clinical size stage
98%
X
SBR grade
98%
X
Histology
98%
Invaded nodes
98%
Skin embolus
8%
X
(c)
Local recurrence.
Variables
NN
LR
Number nodes invaded
98%
X
Lymphatic embolus
95%
X
Ganglion invaded
95%
Necrosis
95%
X
Oestrogen receptors
95%
X
Histology
48%
X
Number tumours
15%
X
Skin invasion
13%
X
(d)
Metastatic recurrence.
Variables
NN
LR
Clinical Size stage
100%
X
Invaded nodes
100%
Progesterone receptors
100%
X
Number of nodes invaded
100%
X
SBR grade
98%
X
Histology
98%
Oestrogen receptors
85%
XTables4(a), 4(c), and 4(d) display variables selections from LR and NN approaches of “Disease free survival”, “Local recurrences”, and “Distal recurrences” analyses.The architecture of MLP neural models for “Specific Mortality” analysis according to variable selection is the following.(i)
NN-varLR. The best model of NN obtained with the inputs of the LR selection (Table4(b)) is described as follows.
(a)
One input layer corresponds to the 5 covariates. The skin embolus covariate, with 2 modalities, corresponds to a binary entry. The other covariates are recoded into as many entries as modalities (3 covariates with 3 modalities and 1 covariate with 5 modalities). The network built that way has 15 binary entries.(b)
One hidden layer composed of 6 neurons with hyperbolic activation function.(c)
One output layer composed of one neurone with logistic activation function.The same types of MLP were built for “Disease free survival”, “Local recurrences”, and “Distal recurrences” analysis.(ii)
NN-varNN. The best model of NN obtained with the inputs of the NN selection (Table4(b)) is described as follows.
(a)
One input layer corresponding to the 7 covariates. These covariates are recoded into as many entries as modalities (5 covariates with 3 modalities, 1 covariate with 4 modalities, and 1 covariate with 5 modalities). The network built that way has 24 binary entries.(b)
One hidden layer composed of 6 hidden units with hyperbolic activation functions.(c)
One output layer composed of one neurone with logistic activation functions.The same types of MLP were built for “Disease free survival”, “Local recurrences”, and “Distal recurrences” analyses.ROC Curves
According to “Specific Mortality”, the AUROC curves of “Specific Mortality” were very similar between the three models with a slight superiority in favour of the NN models (Figure2(b)). The corresponding sensitivity and specificity optimal values are given in Table 5(b).
Figures2(a), 2(c), and 2(d) display AUROC curves, and sensitivity and Tables 5(a), 5(c), and 5(d) display specificity optimal values for the event “Disease-Free survival”, “Local recurrences”, and “Distal recurrences” analyses.Table 5
Sensitivity and specificity.
(a)
Disease-free survival.
LR
NN-varLR
NN-varNN
Sensitivity
71.5
82.2
80.3
Specificity
68.9
77.9
79.3
False negative rate
28.5
17.8
19.7
False positive rate
31.1
22.1
20.7
Positive predictive value
11.9
18.0
18.6
(b)
Mortality from cancer causes.
LR
NN-varLR
NN-varNN
Sensitivity
80.5
86.7
87.5
Specificity
77.9
76.0
77.3
False negative rate
19.5
13.3
12.5
False positive rate
22.1
24.0
22.7
Positive predictive value
17.4
17.2
18.2
(c)
Local recurrence.
LR
NN-varLR
NN-varNN
Sensitivity
68.6
72.4
72.9
Specificity
65.1
66.7
64.9
False negative rate
31.4
27.6
27.1
False positive rate
34.9
33.3
35.1
Positive predictive value
8.3
9.1
8.8
(d)
Metastatic recurrence.
LR
NN-varLR
NN-varNN
Sensitivity
71.3
70.6
71.9
Specificity
78.1
78.8
78.5
False negative rate
28.7
29.4
28.1
False positive rate
21.9
21.2
21.5
Positive predictive value
25.9
26.4
26.4ROC curves from LR, NN-varLR, and NN-varNN models. (a) Disease-free survival. (b) Mortality from cancer causes. (c) Local recurrence. (d) Metastatic recurrence.
(a)
(b)
(c)
(d)


## 4. Discussion

In order to best assess the comparison between LR and MLP predictions, we needed to gather several conditions regarding the cancer to study and the dataset to analyse. We needed for the cancer a specific combination of a well-described clinical course in the literature and a complex interaction between the covariates to introduce in the models. Breast cancer appeared to be the best one to fully achieve these conditions, and some authors have already shown NN could predict the probable clinical course of breast cancer patients [15, 16]. Regarding the dataset, the best data quality was required (to minimize missing and inconsistent data for the training of the NN), as well as a sufficient followup of the cohort. The median followup of 4.2 years appears reasonable enough even though it is slightly short. The database of the Leon Berard Centre appeared to be highly qualified because of a very small percentage of missing data, an inclusion criterion that is well defined, and a regular update of this database done by a dedicated CRA.The consistency across the different models may be explained by the good quality dataset of the CLB database and emphasizes the relevance of the use of the ANN in predictive analysis in oncology.Regarding the cohort selection, the patients retained for analysis were suffering from primary breast cancer and locally advanced cancer without metastasis. The majority of the cases (89%) were≤T2 stage, and the histology was ductal carcinoma for 74% of them. The idea was to obtain a homogeneous cohort and to be in the situation to enable us to potentially identify prognostic factors. This situation excluded the very poor prognosis and explains the paucity of events to analyse (5.4% specific mortality and 12.5% for the total progressions including local and distal recurrences).If we look at the clinical outputs of our variable selection, the four predictive factors commonly selected for the specific mortality analysis, by both LR and NN approaches, were the following: Clinical size stage, SBR grade, Number of nodes invaded, and Progesterone receptors. It is to be underlined that the first three variables are well known within the medical literature and are related directly to clinical indicators routinely used by the NPI (Nottingham Prognostic Index). The NN models, either NN-varNN or NN-varLR, selected three additional factors, namely, Histology, Number of tumour nodules, and Invaded nodes (axillary lymph nodes). These results are compatible with published ones on other cohorts using Bayesian neural networks [7]. The other predictive factors we found with our NN selection other than those used in the NPI are the hormonal factors (PR and ER). Their role must be underlined here as the PR appeared to be a major predictive factor for the specific mortality, as well as for the distal recurrence study. In addition the ER appeared to be a major predictive factor for DFS and the local recurrence. The protective role of both receptors was already known even in terms of time-depending joint effects with tumour size or histology [2] but the respective role of PR and ER split into local and distal recurrences was not described so far. These results are worth exploring with more accuracy in further studies. Regarding the comparison between the performances of the three models, the main results we found consisted in showing that for breast cancer-specific mortality and DFS analysis, the areas under curves appear to be greater with the NN models than the LR (better sensitivity as well as specificity). These results underlined the predictive accuracy of the NN models comparing with the LR and, their relevance as predictive tools. Regarding the recurrence studies, the ROC curves were not as good as those of specific mortality and DFS. Nevertheless the AUROCs were somewhat similar between the LR and NN models, with a slight improvement in favour of the NN models.As previously described, we decided to choose a MLP Neural Network for this specific work. One reason is that MLP is the ANN most widely applied to real-world problems in medical diagnosis and prediction; because of the numerous NN models built in this study, only one type of ANN is used. Other types of NN may have been used such as the Probabilistic Neural Network (PNN). PNN is particularly adapted to stepwise procedures aimed at selecting and classifying prognostic factors from small datasets [17]. Moreover some authors consider MLP to be superior to PNN [9].One of the criticisms towards neural networks is that their process inside is unknown, and some authors consider them as “black boxes”. In order to prevent this criticism and also to enhance as much as possible the NN selection process we decided to use several variables selection techniques perfectly coded and to use one penalty for some selection methods.Using these three different techniques for the variables selection may be criticized as a time-consuming process. It was here a guarantee for the best selection and for avoiding overfitting, which is the main limit of the neural networks. The penalty was used to penalise the big sets of variables with a view to improving the generalization capability of networks. The value of the penalty chosen had a substantial impact on the variable selection. We decided therefore to perform each method half of the time without any penalty and the other half of the time with a penalty equal to 0.0001. A total of 120 selections per covariate were performed with each method of variable selection. This total number of selections increases considerably the time variable selection process but we expected a gain in improvement of the selection. The results we obtained tended to confirm our choice by showing greater AUROC for the mortality and DFS analysis particularly.A limitation of our work is that there is a need for an external validation with a second and independent dataset. We are planning to carry out this extension of the project, and for this reason we think our results should be considered as exploratory rather than predictive. The main objective was to compare standard predictive tools to innovative ones in the medical field, and in oncology in particular. This work brought some clinical insights to be confirmed further in the field of breast cancer prognosis. Another limitation, and probably the major one, is that the present study did not investigate complex time-depending effects of prognostic factors of breast cancer over followup time. The definition of risk categories based on tumours or patients’ characteristics may evolve in the course of the followup according to the disease dynamics. Some authors developed the PLANN (with a partial logistic artificial neural network) approach for the analysis of the hazard function as a function of time and covariates for censored survival time data [2] showed that patients with small tumours with high ER levels and Invasive Ductal Carcinoma plus Invasive Lobular Carcinoma histology could be at high risk of disease recurrence in the medium to long term and consequently should be carefully monitored. They also showed a joint time-dependent effect of histology and ER. Additional analysis taking into account all censored variables must be carried out to improve these models predictivity.In conclusion, this paper presents an evaluation tool for the prognosis of breast cancer on a cohort of nonmetastatic patients using clinical, pathological, and immunohistochemical data. The results of this work, whose main aim was to compare the LR and NN performances in predictions, have to be considered as exploratory results rather than conclusive results for predictions. Our neural network selection approach highlights some different inputs for the models from classical statistical selections. All our input selections were validated by clinicians. We hope this work will convince clinicians to use commonly ANN for the extraction of large dataset patterns in prognostic factors, at risk group definitions, and to envisage these tools as a decision support to appropriate treatments for the individual patient. ANN should be considered powerful predictive tools, to be routinely added to standard logistic regression. The next step will be the development of a web-based tool for community use.



---

*Source: 309841-2010-08-23.xml*